Kurt attended Stanford University and the University of Kansas School of Medicine. He completed medical residencies at the University of Kansas and Johns Hopkins. He is board certified in anatomic pathology, clinical pathology, blood banking and transfusion medicine. He completed an immunology fellowship at the US National Institutes of Health. His work experience has included the FDA as a Medical Officer in the Center for Biologics, Deputy Director of the FDA Division of Cell and Gene Therapy, Assistant Professor at Children’s National Medical Center in Washington DC and several leadership positions in private industry (including Transkaryotic, ViaCell and Hospira). He is currently Chief Medical Officer for Cell Medica, and is based in Houston, TX, USA. He has been active in the International Society for Cellular Therapy (ISCT) and is currently Past President and Advisory Board Chair of ISCT. He serves or has served on the scientific advisory boards of 4 other companies. He is a grant reviewer for the California Institute of Regenerative Medicine (CIRM). He is an active member of several other scientific societies including AABB, International Society for Stem Cell Research, American Society of Hematology, and American Society for Blood and Marrow Transplantation; he has previously served on the FDA Cell, Tissue and Gene Therapy Advisory Committee. Kurt attended Stanford University and the University of Kansas
Randall Ostroff, MD is a board certified anesthesiologist with over 25 years of clinical practice experience, predominately in private practice. Randy was born in Elmhurst, Illinois and raised in the Chicago area. After completing his BS at the University of Illinois (Champaign-Urbana) he received his Medical Degree at The Chicago Medical School. He completed his residency in Anesthesiology at Michael Reese Hospital in Chicago and subsequently held the position of Chairman & Medical Director, Department of Anesthesiology at MacNeal Hospital in Berwyn, IL for nearly 20 years.
Dr. Ostroff also has considerable experience in the pharmaceutical industry, having served 8 years as a Global Medical Director for Abbott, where his accomplishments, amongst others, included 2 Presidents Awards. During the past 10 years, he has served as a consultant to several pharma companies, most recently Paion AG. Paion is a German based company who are the developers of remimazolam, a benzodiazepine with unique metabolism recently having completed phase III trials targeted for a conscious sedation indication in the U.S.
NDA filing is planned for Q1 2018.